Register for AllyCon 2024
Join us for a three-day experience where patients, caregivers, and advocates unite against colorectal cancer. Register by October 14 for early bird pricing.
Our bodies have a gene that produces the dihydropyrimidine dehydrogenase enzyme, which helps break down certain medications in the liver.
If there is mutation in the gene, your body will not produce enough of the dihydropyrimidine dehydrogenase enzyme. This condition is called dihydropyrimidine dehydrogenase deficiency (DPD).
Having DPD can cause fluorouracil-based chemotherapy drugs (which are commonly used in colon cancer treatment) to build up in your body and cause severely toxic reactions.
Note: It has been shown that pretreatment genetic testing for DPD may reveal a need to reduce fluoropyrimidine-based treatments (fluorouracil [FU], capecitabine, and other analogs) to avoid potential lethal toxicities.
Because DPD mutations occur in less than 3% of the population, testing is usually not required unless a patient has an adverse reaction during treatment with fluorouracil-based chemotherapy drugs. The FDA advises physicians to inform patients of the potential for serious and life-threatening adverse reactions due to DPD deficiency. They should also discuss with patients whether they should be tested to determine their risk when using fluoropyrimidine-based chemotherapy.
If you are experiencing side effects such as uncontrollable nausea, vomiting, or diarrhea, very low blood counts, high fevers, or extreme weakness during treatment with fluorouracil-based chemotherapy drugs, contact your doctor immediately.
The treatment option is for patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer (CRC) who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
Statistics suggested that Christy’s odds of survival were grim, so she leaned into her faith and kept a positive outlook. She tried to control what she could. And, critically, she received biomarker testing.
Michelle Cappel owes a lot to colorectal cancer biomarker testing — seven years of life and counting.